Dali Pharmaceuticalco.,Ltd reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 100.46 million compared to CNY 129.14 million a year ago. Revenue was CNY 100.46 million compared to CNY 129.14 million a year ago.

Net loss was CNY 11.48 million compared to CNY 5.95 million a year ago. Basic loss per share from continuing operations was CNY 0.0522 compared to CNY 0.0271 a year ago. Diluted loss per share from continuing operations was CNY 0.0522 compared to CNY 0.0271 a year ago.